What's Happening?
Longhorn Vaccines and Diagnostics is set to present a late-breaking poster at the ESCMID Conference on Vaccines, showcasing their LHNVD-303 therapy aimed at combating antimicrobial resistance (AMR). The presentation will highlight the cross-reactive binding and opsonization of S. aureus and E. coli by a single antibody, which forms the core of LHNVD-303. This therapy targets conserved bacterial signatures and circulating fragments that fuel inflammation, offering a first-in-class immune-sparing approach to AMR prevention and treatment. The conference will take place in Lisbon, Portugal, from September 10-13, 2025.
Why It's Important?
The development of LHNVD-303 represents a significant advancement in addressing AMR, a growing global health concern. By targeting conserved bacterial signatures, the therapy aims to reduce inflammation and prevent infections without disrupting the microbiome. This approach could lead to fewer infection crises and lower inflammatory burdens, contributing to improved public health outcomes. The research aligns with Longhorn's mission to develop broad coverage vaccines and diagnostic tools for global health challenges.
What's Next?
Longhorn is advancing LHNVD-303 and other monoclonal antibody combinations through its anti-PAMP platform, with plans to explore additional infections related to AMR. The company is designing pre-clinical studies to further investigate the therapy's potential in high-risk populations and as an add-on treatment in bloodstream infections and sepsis. The presentation at ESCMID 2025 marks a key milestone in Longhorn's efforts to combat AMR and improve infection control strategies.
